Outcome of posterior chamber phakic intraocular lens procedure to correct myopia

To assess the safety and efficacy of the implantable contact lens [ICL[TM]] to treat myopia. Clinical, retrospective, single center, non-randomized case series. Sixty-nine eyes of 46 patients with myopia ranging from -3.00 to 25.00 D were included in this study. Implantation of the ICL[TM]. Main outcome measures: Uncorrected Visual Acuity [UCVA], refraction, best spectacle corrected visual acuity [BSCVA], adverse events, operative and postoperative complications, subjective assessment and symptoms. The mean follow-up was 12.35 +/- 6.13 [SD] months [range, 6 months-32 months]. At the last visit, 49.20% of eyes had 20/20 or better UCVA compared to preoperative 20/20 or better BSCVA of 31.9% of eyes; 69.23% of eyes had postoperative UCVA better than or equal to preoperative BSCVA. The mean manifest refractive cylinder was 1.93 +/- 1.21 D at baseline and 1.00 +/- 0.92 D postoperatively. The mean manifest refraction spherical equivalent [MRSE] was -11.70 +/- 4.24 D preoperatively and -0.69 +/- 1.13 D postoperatively. A total of 69.8% of eyes were within +/- 0.5 D of the predicted MRSE; 84.1% were within +/- 1.0 D, and 88.90% were within +/- 2.0 D. BSCVA of 20/20 or better was achieved in 64.6% of eyes postoperatively, compared to 31.9% preoperatively. Mean improvement in BSCVA was 1line. One eye [1.5%] lost >/= 2 lines of BSCVA at the last visit, whereas 20% of eyes improved by >/= 2 lines. A total of 56.92% of cases gained >/= 1 line of BSCVA and 4.62% of cases lost >/= 1 line. Four ICL lenses were removed without significant loss of BSCVA, and 2 eyes with clinically significant lens opacities were observed. Four eyes [5.8%] developed a pupillary block the first day postoperatively. One eye [1.4%] developed a hypotony and AC shallowing. Implantation of ICL for the correction of myopia was a safe procedure with good visual and refractive results from the early postoperative period to 1 year. Long-term follow-up is required to confirm the long-term safety of this implant.

Comparison of levobupivacaine 0.5% or bupivacaine 0.5% both in a mixture with lidocaine 2% for superficial extraconal blockade

To evaluate the quality and efficacy of Peribulbar blockade for superficial extraconal anesthesia with levobupivacaine 0.5% versus bupivacaine 0.5%, both combined with lidocaine 2% for patients undergoing phacoemulsification. In this prospective, double blind study, 150 patients were randomly divided into two groups: group-1 received a Peribulbar block [PB] with a mixture of evobupivacaine 0.5% and lidocaine 2% while group-2 received a PB with a mixture of bupivacaine 0.5% and lidocaine 2%. The block was performed by insertion of a short needle [15 mm] in infra-temporal space just above inferior orbital notch. An initial volume of 6 9 ml of either mixture was injected until total upper eyelid drop. Akinesia score was assessed at 2, 5, and 10 min after the block. The degree of pain was assessed by a verbal rating scale immediately after block, at the end of surgery and 4 h postoperatively. The patients and surgeons were asked to rate their satisfaction level of the quality of block postoperatively. Data were analyzed with the unpaired, two-tailed t-test and the Chi-square test as appropriate. P < 0.05 was considered statistically significant. There were no significant differences between groups with respect to the akinesia score [P = 0.2] at 2, 5, and 10 min, the number of supplementary injections [P = 0.84] and initial and total required volume of local anesthetics [P = 0.80 and 0.81, respectively]. There was no significant difference between the groups regarding surgeon and patient satisfaction [P = 0.53 and P = 0.74, respectively]. Similarly the verbal rating scales assessed at three different occasions were not significantly different between the groups [P > 0.05 all cases]. The need for additional intra-operative topical anesthetic was also similar between the groups. [P = 0.69]. Superficial extra-conal block with a mixture of levobupivicaine 0.5% and lidocaine 2% or bupivicaine 0.5% and lidocaine 2% provides similar block quality and efficacy

Successful removal of a conjunctival myxoma

A 45-year-old woman presented with conjunctival myxoma in the right eye. A mixture of healon and trypan blue solution 0.06 mg was injected through a 27-gauge needle into the conjunctiva to delineate the lesion to achieve complete removal. This technique is effective in delineating the myxoma while preserving its integrity during removal. It may also help in lowering recurrence